Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

A Novel Phthalimide-Derivative, TC11, Induced G2/M Arrest and Apoptosis of High-Risk Myeloma Cells By Interacting with Nucleophosmin1 and α-Tubulin, but Not By Binding to Celeblon

Misa Nakamura, Daiju Ichikawa, PhD, Shuji Aida, Nahoko Hashimoto, Wakana Murota, Ryo Uozaki, Mikio Okayama, MD, Kota Fujimori, Yuko Yonemura, Noriko Tabata, PhD, Hiroshi Yanagawa, PhD, Maiko Matsushita, MD PhD, Yutaka Hattori, MD PhD

Blood (2017) 130 (Supplement 1): 5377.

https://doi.org/10.1182/blood.V130.Suppl_1.5377.5377

Published: 2017

Journal Articles

Komaroviquinone-Derivatives, Revealed Anti-Tumor Effect on High-Risk Multiple Myeloma Cells In Vitro as Well as In Vivo

Mariko Sato, Kota Fujimori, Shotaro Kitabatake, Mikio Okayama, MD, Daiju Ichikawa, PhD, Yutaka Suto, PhD, Genji Iwasaki, PhD, Fumiyuki Kiuchi, PhD, Takashi Yamaguchi, Arimi Ueda, Shuji Aida, Hitomi Nakayama, MD, Maiko Matsushita, MD PhD, Yutaka Hattori, MD PhD

Blood (2016) 128 (22): 2100.

https://doi.org/10.1182/blood.V128.22.2100.2100

Published: 2016

Journal Articles

10 Years History of Cost-Effectiveness for 209 Newly Diagnosed Multiple Myeloma Patients at a Single-Institute in Japan

Kenshi Suzuki, MD PhD, Tomofumi Yamamoto, Masahiro Ikeda, MD, Tomomi Takei, MD, Nobuhiro Tsukada, MD PhD, Tadao Ishida, MD PhD, Arimi Ueda, Daiju Ichikawa, PhD, Maiko Matsushita, MD PhD, Yutaka Hattori, MD PhD

Blood (2016) 128 (22): 5620.

https://doi.org/10.1182/blood.V128.22.5620.5620

Published: 2016

Journal Articles

Drug Design for Overcoming High-Risk Myeloma and Identification of Novel Binding Proteins to Immune-Modulatory Drugs

Masashi Hozumi, Daiju Ichikawa, PhD, Maiko Matsushita, MD PhD, Eriko Kamiyama, Hiroshi Yanagawa, PhD, Noriko Tabata, PhD, Shotaro Kitabatake, Arimi Ueda, Takashi Yamaguchi, Mariko Sato, Yutaka Hattori, MD PhD

Blood (2015) 126 (23): 1800.

https://doi.org/10.1182/blood.V126.23.1800.1800

Published: 2015

Journal Articles

Development of a Novel Phthalimide Derivative, Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts

Yutaka Hattori, MD PhD, Maiko Matsushita, MD PhD, Noriko Tabata, Hirokazu Shiheido, Hiroshi Yanagawa, PhD, Arimi Ueda, Masashi Hozumi, Shotaro Kitabatake, Daiju Ichikawa

Blood (2014) 124 (21): 5718.

https://doi.org/10.1182/blood.V124.21.5718.5718

Published: 2014

Journal Articles

Codon 72 Polymorphism Of TP53 Gene Is a Novel Prognostic Marker For Thalidomide Therapy In Multiple Myeloma

Yutaka Hattori, MD, PhD, Yurika Ikeda, Yuya Suzuki, Daiju Ichikawa, PhD, Maiko Matsushita, MD, PhD

Blood (2013) 122 (21): 1891.

https://doi.org/10.1182/blood.V122.21.1891.1891

Published: 2013

Journal Articles

TC11, a Novel Phthalimide Derivative, Directly Binds to NPM1 and Induced Apoptosis of High-Risk Myeloma Cells Via Centrosomal Disruption

Saito Sosei, Kana Yoshikawa, Noriko Tabata, PhD, Hiroshi Yanagawa, PhD, Tsukasa Oikawa, PhD, Wenlin Du, MD, PhD, Taketo Yamada, MD, PhD, Maiko Matsushita, MD, PhD, Junya Seki, Kaoru Tohyama, MD, PhD, Yutaka Hattori, MD, PhD

Blood (2012) 120 (21): 1841.

https://doi.org/10.1182/blood.V120.21.1841.1841

Published: 2012

Journal Articles

Detailed Investigation On Characteristics of Japanese Patients with Chronic Phase CML Who Achieved a Durable CMR After Discontinuation of Imatinib – an Updated Result of the Keio STIM Study.

Eri Matsuki, MD, PhD, Yukako Ono, MD, Koharu Tonegawa, Masatoshi Sakurai, MD, Hiroyoshi Kunimoto, MD, Jo Ishizawa, MD, PhD, Norisato Hashimoto, MD, Takayuki Shimizu, MD, PhD, Akiko Yamane, MD, PhD, Maiko Matsushita, MD, PhD, Kenji Yokoyama, MD, PhD, Shinichiro Okamoto, MD, PhD

Blood (2012) 120 (21): 2788.

https://doi.org/10.1182/blood.V120.21.2788.2788

Published: 2012

Journal Articles

Discontinuation of Imatinib in Patients with CML and Sustained Complete Molecular Response (CMR) for Over 2 Years in the Japanese Population – An Interim Analysis of KEIO STIM Study,

Eri Matsuki, MD, PhD, Yukako Ono, MD, Masatoshi Sakurai, MD, Hiroyoshi Kunimoto, MD, Jo Ishizawa, MD, PhD, Takayuki Shimizu, MD, PhD, Akiko Yamane, MD, PhD, Maiko Matsushita, MD, PhD, Kenji Yokoyama, MD, PhD, Shinichiro Okamoto, MD, PhD

Blood (2011) 118 (21): 3765.

https://doi.org/10.1182/blood.V118.21.3765.3765

Published: 2011

Journal Articles

A Novel Anilinoquinazoline Derivative Inhibits Growth of High-Risk Myeloma Cells In Vivo and Regulates Differentiation of Osteoclasts

Yoshie Ozaki, Yuhei Naito, Hiroshi Yanagawa, PhD, Yuya Suzuki, Wenlin Du, MD, PhD, Taketo Yamada, MD, PhD, Koichi Matsuo, MD, PhD, Nobuhide Doi, PhD, Shiro Iijima, PhD, Maiko Matsushita, MD, PhD, Kayoko Tahara, PhD, Yutaka Hattori, MD, PhD

Blood (2010) 116 (21): 4076.

https://doi.org/10.1182/blood.V116.21.4076.4076

Published: 2010

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A Novel Phthalimide-Derivative, TC11, Induced G2/M Arrest and Apoptosis of High-Risk Myeloma Cells By Interacting with Nucleophosmin1 and α-Tubulin, but Not By Binding to Celeblon

Komaroviquinone-Derivatives, Revealed Anti-Tumor Effect on High-Risk Multiple Myeloma Cells In Vitro as Well as In Vivo

10 Years History of Cost-Effectiveness for 209 Newly Diagnosed Multiple Myeloma Patients at a Single-Institute in Japan

Drug Design for Overcoming High-Risk Myeloma and Identification of Novel Binding Proteins to Immune-Modulatory Drugs

Development of a Novel Phthalimide Derivative, Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts

Codon 72 Polymorphism Of TP53 Gene Is a Novel Prognostic Marker For Thalidomide Therapy In Multiple Myeloma

TC11, a Novel Phthalimide Derivative, Directly Binds to NPM1 and Induced Apoptosis of High-Risk Myeloma Cells Via Centrosomal Disruption

Detailed Investigation On Characteristics of Japanese Patients with Chronic Phase CML Who Achieved a Durable CMR After Discontinuation of Imatinib – an Updated Result of the Keio STIM Study.

Discontinuation of Imatinib in Patients with CML and Sustained Complete Molecular Response (CMR) for Over 2 Years in the Japanese Population – An Interim Analysis of KEIO STIM Study,

A Novel Anilinoquinazoline Derivative Inhibits Growth of High-Risk Myeloma Cells In Vivo and Regulates Differentiation of Osteoclasts

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only